Lifehealthcare Group Ltd reports impressive profit results: Should you buy?

Lifehealthcare Group Ltd (ASX:LHC) has performed superbly since its IPO.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What: The relatively unknown Lifehealthcare Group Ltd (ASX: LHC) has reported an outstanding half-year result.

The distributor of medical devices listed on the ASX just over one year ago and so far the company certainly hasn't disappointed initial public offer (IPO) investors with the share price up over 40%, which is outstanding compared with the 14.6% return from the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) over the same time period.

For its interim results the group exceeded its prospectus forecast for net profit after tax but before amortisation (NPATA) by 19.5% with a figure of $4.3 million achieved. Revenue growth was also impressive, coming in 15% higher than the prior period at $48.4 million.

So what: The explanation for the significantly higher profit result was strong growth in the higher margin implantable devices business and a higher margin capital equipment product mix.

The growth in implantable device revenue was achieved via a greater number of surgeons using the company's implants and increasing penetration of products amongst both new and existing surgeons.

Meanwhile, the introduction of new capital equipment products helped boost growth across the Cardiology, Operating Room and Neurophysiology channels.

What now: Shareholders have a 7.5 cent per share dividend, which will be 76% franked to look forward to in March.

It should be noted that Lifehealthcare has now used up all of its franking credits and management provided guidance that it does not expect any further dividends paid prior to 30 June 2016 to have any franking attached to them.

Management also provided guidance for the full year for revenue growth in the low double digit range and for earnings before interest, tax, depreciation and amortisation (EBITDA) margins consistent with historical performance.

With the company operating in the attractive healthcare industry which is experiencing favourable tailwinds for many in the sector (including CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC)) it could be worth long-term investors considering as it trades on an undemanding multiple.

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned.  

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »